Integumen PLC’s (LON:SKIN) Gerry Brandon caught up with Proactive London’s Andrew Scott to discuss three new contracts they’ve won worth £290,000 in total.
Integumen PLC (LON:SKIN) CEO Gerry Brandon ‘ move into clinical trials.
Integumen PLC (LON:SKIN) CEO Gerry Brandon speaks to Proactive London’s Andrew Scott soon after announcing the roll-out of a new Labskin test designed to clone the skin of volunteers in clinical
Tekcapital plc (LON:TEK) Salarius secures first commercial order
Salarius launches production of MicroSalt® and secures first commercial order
Leigh Hughes, chief executive of Next Green Wave Holdings Inc (CSE:NGW) Interview
Effective today, NGW will commence its cultivation program and receive its first plantlets to accommodate a perpetual harvest cycle.
Integumen PLC (LON:SKIN) Chief Executive Gerry Brandon
Integumen builds out Labskin AI platform with RinoCloud acquisition
ValiRx PLC (LON:VAL) Dr Satu Vainikka, CEO Interview
We caught up with Dr Satu Vainikka, CEO of VAL at this year UK Investors Show held in the QE2 building in London.
WideCells Group PLC (LON:WDC) New Media Business Created
New Media Business Created, Board Appointments and Proposed Name Change to Iconic Labs Plc
NetScientific PLC (LON:NSCI) Share Price Movement
NetScientific plc (AIM: NSCI) notes its recent share price movement and confirms that it is not aware of any reason for such movement.
Faron Pharmaceuticals Ltd (LON:FARN) UK CTA approval
Substantial immune activation taking place post-Clevegen administration UK CTA approval
Motif Bio PLC (LON:MTFB) Complete Response Letter from the FDA
Graham Lumsden, Chief Executive Officer of Motif Bio, said: “We are disappointed for patients and providers seeking an alternative antibiotic to treat ABSSSI. We intend to request a meeting with
OKYO Pharma Limited (LON:OKYO) Corporate Update
Since its inception the company (OKYO Pharma Ltd. ”OKYO”) has progressed its R&D programs focused on its assets Chemerin and BAM8.
